initi coverag
hit best shot initi overweight
invest summari initi coverag inc
overweight rate price target expect approv
end year potenti upcom catalyst drive
physician want less costli altern allergan botox
physician survey disappoint allergan consist
price increas abl pass onto patient creat
opportun plan sell
discount botox addit aesthet kol
invest parent organ alpheon creat financi
align success also think kol influenti
aesthet industri help acceler adopt
price flexibl unlik competitor expect
 neurotoxin without therapeut indic aesthetic-onli
non-reimburs product strategi allow meaning strateg advantag
 includ price market flexibl evolu intend util
flexibl drive market adopt program promot
event sampl program price strategi competitor
pursu toxin also approv medic use
 clinic data look better allergan botox eu korea
ran phase studi compar allergan botox
studi almost demonstr superior botox trend
better botox time point measur notabl demonstr
efficaci month exist toxin market durat
month label
interest compani consolid industri mani publicli trade
dermatolog aesthet compani acquir larger cap pharma
leverag asset across establish commerci infrastructur
allergan valeant johnson johnson consolid space
dermatolog aesthet compani acquir mean
ev/sal rang chang control issu
next stock move catalyst would approv pdufa
date approv may would repres upsid investor
expect given outstand approv anticip street
summer
 valuat use blend ev/ebitda dcf analysi arriv
disclosur section may found page
tabl content
upcom catalyst event
compani histori overview
glabellar line
industri overview competit
relationship daewoong
bull bear base case analysi
wait approv expect end year
base dilig dermatologist plastic surgeon appreci valu proposit
botulinum toxin product nearli ident allergan botox plan sell
discount botox save physician ten thousand dollar cost
potenti even annual therefor think could pick meaning
market share approv
four reason think stock repres compel invest opportun
physician want less costli altern allergan botox physician survey
disappoint allergan consist price increas abl pass onto
patient creat opportun plan sell
discount botox addit aesthet kol invest parent
organ alphaeon creat financi align success also think
kol influenti aesthet industri help acceler adopt
botox price increas consist recent year accord center medicar
medicaid servic averag sale price asp botox per vial june
nearli juli asp approxim per vial
base dilig mani physician express frustrat increas neurotoxin price
non-surg cosmet procedur largest segment aesthet industri
nonsurg cosmet procedur compris total cosmet procedur volum
non-surg procedur grew compar growth surgic aesthet
procedur almost botulinum toxin procedur perform growth
expect global self-pay medic aesthet neurotoxin market gener revenu
estim market grow global self-pay medic aesthet
market estim grow compound annual growth rate compound-annual-growth-rate
compris largest portion market
price flexibl unlik competitor expect
neurotoxin without therapeut indic aesthetic-onli non-reimburs product strategi
allow meaning strateg advantag includ price market flexibl
intend util flexibl drive market adopt program promot
event sampl program price strategi competitor pursu
toxin also approv medic use
aesthet market self-pay healthcar remov reimburs risk
focus sole aesthet market therapeut indic well
flexibl price self-pay market evolu interact
govern insur reimburs
clinic data look better allergan botox eu korea ran phase
studi compar allergan botox studi almost demonstr
superior botox trend better botox time point measur notabl
demonstr efficaci month exist toxin market durat month
label
clinic data look better botox eu korean phase studi phase
trial botox use compar korean eu phase data compar botox
case favor botox data miss superior page
bodi report detail korean data see page bodi
report detail eu data korean studi trend better botox time
point measur week see bottom page bodi report
detail approv like data label show
effect five month botox durat claim label month page
data
interest compani consolid industri mani publicli trade dermatolog
aesthet compani acquir larger cap pharma leverag asset across
establish commerci infrastructur allergan valeant johnson johnson
consolid space dermatolog aesthet compani acquir mean
ev/sal rang chang control issu
upcom catalyst event
next import catalyst compani pdufa date ema
decis in-licens partnership and/or acquisit expand product offer
pdufa date approv may would repres upsid investor
expect given outstand street anticip approv summer
exhibit catalyst event calendar
datedriverupcom studi amwc asap medic datejun studi medic meetingmid-aug sept soft launch prelaunch approvalsourc cantor fitzgerald research compani report march
compani histori overview
intend launch brand neurotoxin global cash pay aesthet market
estim worth estim aesthet neurotoxin long term
strategi build diversifi medic aesthet compani target neurotoxin
compani lead product submit fda bla juli
anticip pdufa date may also submit ema file
review decis expect
obtain neurotoxin botulinum toxin type exclus licens
daewoong licens includ aesthet indic eu
canada australia russia ci south africa well co-exclus licens japan
approv korea sinc novemb market nabota option
exercis licens territori therapeut indic end
compani assign current hold trust alphaeon septemb
employe half full time half assign alphaeon
work part time
incorpor delawar headquart irvin california
septemb enter agreement daewoong pharmaceut co
ltd daewoong gain exclus licens develop market dwp-
daewoong neurotoxin unit state eu canada australia russia
sch-aeon llc formerli known strathspey crown hold llc sch
acquir outstand equiti seri transact exchang
membership interest sch
approv south korea novemb treatment glabellar
line brand name nabota
sch contribut equiti acquir alphaeon result
becom wholli own subsidiari alphaeon
initi five-studi program eu canada
adult particip studi ran septemb august
august murthi simhambhatla appoint ceo alphaeon novemb
mr simhambhatla appoint ceo mr simhambhatla resign
posit ceo alphaeon
may submit bla fda juli eu submiss
accept ema
evoluss nd submit canada octob
glabellar line
inject botulinum toxin type neurotoxin studi
subject first known neurotoxin file fda sinc botox given
current aesthet physician familiar use botox expect easili integr
practic botox kda neurotoxin unlik botox
focu sole aesthet indic offer better price market flexibl
compar neurotoxin includ botox price especi advantag allergan
taken number price increas botox last year physician unabl pass
full impact price increas onto patient uniqu posit
plastic surgeon dermatologist found physician parent compani
inject potenti less costli safe altern current product
market includ dysport xeomin market leader botox approv may
expect soft launch mid-august septemb full launch
conserv model sale time expect peak sale
evolu expect build commerci infrastructur sale forc
sale repres grow time base dilig think
aesthet sale botulinum toxin could grow annual even discount botox
repres sale market share estim higher rate penetr base unit
per exhibit
cantor fitzgerald research compani report
outsid expect use distributor sell expect eu
approv addit ex-u approv continu assum
royalti evolu ex-u sale gener ex-u end market
sale evolu expect decis eu file second half
submit new drug submiss canada accept octob
toxin market total market botulinum toxin procedur per year botulinum procedur per year per person peopl receiv botulinum toxin cosmet market share use price per dose per dose excl physician fee markup dose per cantor fitzgerald research compani reportsfisc year end decemb exhibit ex-u market model
cantor fitzgerald research compani report
focu aesthet market strategi allow
easili integr aesthet physician practic drive use
evolu market aesthet indic largest market opportun
glabellar line glabellar line result gather tissu
eyebrow fold caus repeat action underli muscl associ
facial express year squint frown tend leav deep wrinkl skin
eyebrow bridg nose across forehead corner eye mani
peopl frown line produc angri sad look detract pleasant facial appear
physic emot social reason treat frown line forehead furrow includ improv
appear enhanc self-esteem common cosmet use market leader botox
treatment glabellar line gener revenu allergan
indic accord american societi aesthet plastic surgeri botulinum toxin treatment
number one nonsurg cosmet procedur allergan rais price botox
meaning numer time last year offer custom
physician altern botox well offer possibl grow overal market
agreement daewoong run septemb later five year post
approv septemb agreement automat renew post initi expiri date
unlimit number three year term provid meet undisclos perform
requir per agreement own market author clinic trial result
licens countri evolu own bla submiss submiss eu
nd submit canada
toxin market ex-u total market botulinum toxin procedur per year botulinum procedur per year per person peopl receiv botulinum toxin cosmet market share use price per dose per dose excl physician fee markup dose per year assum four month cantor fitzgerald research compani reportsfisc year end decemb march
licens daewoong septemb commenc clinic trial
contain kda botulinum toxin type produc bacterium clostridium
botulinum neurotoxin complex molecular weight neurotoxin
botox kda activ neurotoxin compon rest complex made
accessori protein mechan action type botulinum
complet phase trial eu approv expect may
respect met fda eu regulatori bodi
develop stage provid feedback compani clinic program
believ bode well potenti approv later year total studi five
studi across eu canada studi includ three phase multicent random
control singl dose studi two open label multipl dose long-term phase studi total
patient moder sever glabellar line maximum frown particip studi
trial file potenti approv
 complet phase studi two ident placebo-control pivot
studi enrol subject total long term safeti studi
also includ part file
exhibit summari evolu clinic trial
cantor fitzgerald research compani report
ident multicent random doubl blind placebo control phase
trial subject trial assess moder sever glabellar line maximum frown
assess investig patient use photonumer glabellar line scale
gl subject randomli assign receiv either singl treatment placebo
salin primari endpoint portion respond day endpoint composit
endpoint respond describ subject point greater improv
gl day assess maximum frown investig subject
independ fda guidanc deem endpoint clinic meaning composit
pivot phase safeti efficacyu pivot phase safeti efficacyu phase ii long-term safetyu phase ii long-term safetypopul adult year moder sever glabellar line glabellar line scale gl score maximum frown independ assess bothinvestig assess ia subject assess sa adult year moder sever glabellar line gl score maximum frown independ assess bothia sa adult year moder sever glabellar line gl score maximum frown assess ia adult year moder sever glabellar line gl score maximum frown independ agre bothia samulticentermulticentermulticentermulticenterrandom blinddoubl blindopen labelopen labelplacebo controlledplacebo controlledmultipl dose initi treatment plu three repeat treatment multipl dose initi treatment plu three repeat treatment singl dosesingl day day day day durationsingl treatment singl treatment unit unit salin salin placebo number random random treat treat sitesunit statesunit statesunit statesunit statesproport subject classifi respond day subject classifi respond day composit endpointa composit endpointa respond subject point improv gl day day maximum frowna respond subject point improv gl day day maximum frownstudydesign includ unit maximum unit maximum treatmentsprimari endpointnon efficaci endpoint exploratorynon efficaci endpoint exploratori march
met primari endpoint show superior placebo
patient met primari endpoint compar placebo absolut
differ confid interv trial patient
met primari endpoint compar placebo absolut differ
exhibit phase glabellar line studi
point greater composit score studi requir investig subject agre
simultan gener result lower respond rate non-composit studi xeomin
dysport repres two botulinum toxin type product also conduct trial use two
point greater composit respond rate although cant compar across studi refer
xeomin two point greater respond rate phase studi per fda label
dysport rate botox trial respond defin
grade least moder improv botox trial investig assess
least two point improv compar
subject assess least two point improv botox compar
exhibit botox investig subject assess respond rate subject
year day
secondari endpoint trial includ measur point improv gl maximum
frown beyond day assess investig subject respond rate
day earli termin assess
respect respond rate respect
time point assess statist signific compar placebo
addit exploratori efficaci analys studi conduct
investig one point greater improv assess either subject
investig variou day maximum frown base gl compar
placebo day day day day day day day earli termin
exhibit phase glabellar line trial exploratori endpoint point improv
gl maximum frown
studi also assess exploratori endpoint investig patient assess
global aesthet improv scale gai gai five-point scale
evalu subject investig determin aesthet outcom subject much
improv improv chang wors much wors rate posit respond
assess either subject investig much improv improv cours
studi provid
exhibit phase glabellar line trial exploratori endpoint global aesthet
studi well toler advers event ae rate
placebo group group seriou advers event group
assess drug relat placebo group also similar percentag
subject experienc assess investig studi drug relat placebo
subject subject eyelid eyebrow ptosi rate droop
upper eyelid eyebrow respect group ae rate
placebo drug relat sae placebo
group also similar percentag subject experienc ae assess
investig studi drug relat placebo subject subject
eyelid eyebrow ptosi rate arm respect overal
incid greater headach group
placebo group eyelid ptosi group placebo group eyelid
ptosi botox glabellar line trial
also studi two long term safeti studi
multi-dos studi last year howev formul lyophil
wherea studi conduct use vacuum dri cours
year patient particip studi subject experi studi drug relat
none seriou total studi experienc occur first
dose advers event experienc third dose subject receiv
averag three dose one year period drug relat seriou occur
subject experienc drug relat ae major occur first visit
combin eyelid ptosi rate studi
eu develop program includ third phase safeti efficaci studi
studi conduct eu canada subject moder sever glabellar line
gl score assess investig provid subject felt glabellar line
psycholog impact subject randomli assign ratio receiv singl
treatment unit unit botox placebo primari endpoint
measur day
primari efficaci endpoint proport respond day respond subject
gl score assess investig maximum frown studi
show superior placebo well non-inferior botox percentag respond
primari efficaci endpoint placebo group ci
botox group ci group ci
absolut differ treatment group placebo
group ci indic superior placebo
botox group ci noninferior versu
botox conclud base lower bound ci absolut differ exceed
pivot phase safeti efficacypopulationhealthi adult year moder sever glabellar line gl score maximum frown assess ia onlyand felt glabellar line import psycholog impactmulticenterrandom blindplacebo activ controlledsingl day durationsingl treatment unit unit botox salin placebo number random sitescanada franc germani sweden unit kingdomproport subject classifi respond day composit endpointa respond subject gl score includ durationtreatmentsprimari endpoint exhibit eu phase glabellar studi meet primari endpoint non-inferior design
well toler trial placebo subject botox
subject subject experienc howev
experienc drug relat drug relat occur trial eyelid
ptosi rate arm botox arm eyebrow ptosi rate
arm botox arm
approv korea novemb glabellar line daewoong develop dwp-
korea market commerci product nabota countri trial form basi
daewoong korean file one phase studi one phase studi studi compar
unit nabota formul unit botox onabotulinumtoxina inject
unit per millilit ml five target site glabellar region adult subject
moder sever glabellar line phase studi includ subject receiv dwp-
nabota receiv botox primari efficaci endpoint respond rate
maximum frown week respond defin subject glabellar line sever scale
score none mild base investig assess glabellar line korean
trial nabota respond rate measur glabellar line sever week
nabota patient compar botox patient trial nabota show
non-inferior botox pre specifi lower limit confid interv
rang ci base lower limit
confid interv surpass pre-determin threshold non-inferior nabota
treatment group determin non-inferior botox
korean phase studi continu show better efficaci botox week
improv rate glabellar line sever maximum frown investig
assess nabota botox measur secondari efficaci
endpoint phase trial respond rate nabota group
week week week week respect botox group respond
rate week week week week respect
nabota well toler drug relat seriou advers event trial
exhibit secondari endpoint improv rate glabellar line sever maximum frown
manufactur agreement daewoong manufactur market
includ eu daewoong construct facil gyeonggi-do south korea
purpos produc facil complet intent compli
fda ema regul fulli valid daewoong cgmp requir
evolu believ facil suffici meet demand fda conduct
cgmp pre-approv inspect facil novemb novemb end
inspect fda issu fda ten inspect observ daewoong
includ need adher improv procedur process document relat
investig non-compli specif batch compon environment
monitor drug substanc test comput system access materi handl staff train
daewoong respond fda plan implement correct action relat
observ await respons fda daewoong believ adequ resolv
observ rais letter ema inspect manufactur site expect
occur first quarter
botulinum toxin patent manufactur process patent daewoong
obtain patent manufactur process protect
combin trademark trade secret protect confidenti agreement proprietari know
licens trademark associ daewoong
superior court state california file june
medytox inc alleg daewoong stole medytox botulinum toxin bacteri strain
daewoong misappropri certain trade secret daewoong interf medytox
plan licens toxin meditoxin evolu
medytox alleg violat california uniform trade secret act ii stolen
strain possess refus return strain iii engag
unlaw unfair fraudul busi act practic violat california bu
prof code iv daewoong agreement invalid violat medytox right
medytox seek actual consequenti punit damag ii reason royalti iii
declar daewoong agreement void unenforc medytox entitl
disgorg properti wrong unjustli retain acquir defend
includ unlaw gain profit iv injunct relief prohibit evolu use licens
daewoong agreement distribut
current stay pend outcom proceed south korea
seoul central district court seoul south korea file octob
medytox initi civil lawsuit relat subject matter california case
alphaeon sch-aeon llc name south korean case
medytox file citizen petit fda seek delay approv
industri overview competit landscap
aesthet market larg grow driven number factor includ age
popul increas focu appear new product launch grow pipelin
product higher dispos incom result good economi non-surg cosmet
procedur addit male aesthet market larg under-penetrated potenti
provid signific growth futur would also note uptak aesthet procedur
millenni robust well
aesthet market self-pay healthcar remov reimburs risk
focus sole aesthet market therapeut indic well
flexibl price self-pay market evolu interact
govern insur reimburs
non-surg cosmet procedur largest segment aesthet industri
nonsurg cosmet procedur compris total cosmet procedur volum
non-surg procedur grew compar growth surgic aesthet
procedur almost botulinum toxin procedur perform growth
expect global self-pay medic aesthet neurotoxin market gener revenu
estim market grow global self-pay medic aesthet
market estim grow compound annual growth rate compound-annual-growth-rate
compris largest portion market
interest compani consolid industri mani publicli trade dermatolog
aesthet compani acquir larger cap pharma leverag asset across
establish commerci infrastructur allergan valeant johnson johnson
consolid space dermatolog aesthet compani acquir mean
ev/sal rang chang control issu pleas see exhibit
detail
exhibit aesthet compani
american spent nearli surgic nonsurg cosmet procedur
procedur women account prime age group
year old rang botulinum toxin hyaluron acid juvederm
yearbuy namesel nameev mm ev /salesaesthet medic naaesthet naaesthet medic medic medic facial filler toxin medic medic nmaesthet medic cantor fitzgerald research compani report ev enterpris valu multipl calcul histor sale ebitda march
nonsurg cosmet procedur last six year botulinum toxin
botulinum toxin botox dysport xeomin hyaluron acid juvederm ultra ultra
voluma perlan restylan belotero maintain spot popular
nonsurg procedur eight year run botox dysport xeomin repres major
medic aesthet botulinum toxin type market botox sale repres
 market share world-wide market share gener revenu
 year dysport xeomin sale repres market
share respect world-wide market share respect gener
revenu respect botox price increas last
two year
botox price increas consist recent year accord center medicar
medicaid servic averag sale price asp botox per vial june
nearli juli asp approxim per vial
base dilig mani physician express frustrat increas neurotoxin price
exhibit aesthet procedur perform
american societi aesthet plastic surgeri
larg establish aesthet neurotoxin market includ wide rang age group
approxim total nonsurg procedur perform gener
patient approxim perform babi boomer patient millenni patient
repres grow segment aesthet neurotoxin market data american societi
surgeon show increas number botulinum toxin
type procedur patient age younger subset age millenni
gener age group made approxim total nonsurg
procedur believ provid sourc futur growth
exhibit distribut inject procedur perform
american societi aesthet plastic surgeri
current botulinum toxin market three main product similar safeti profil subtl
differ market-lead toxin botox mid market share physician like use
toxin treatment outcom well known believ could better efficaci
durat product current market could disrupt market competitor within
number proceduresperc total number proceduresperc total number proceduresperc total growth botulinum toxin includ botox dysport hydroxylapatit acid incl juvederm ultra ultra voluma perlan restylan acid nonsurg number proceduresperc total number proceduresperc total number proceduresperc total number proceduresperc total number proceduresperc total botulinum toxin includ botox dysport hydroxylapatit acid incl juvederm ultra ultra voluma perlan restylan acid nonsurg march
botulinum toxin market ration price competitor dont see entranc
drive price significantli
addit take market share botox potenti benefit
increas use aesthet product men well growth outsid imca
intern master cours age scienc expect asia/pacif latin america
fastest grow market grow combin total procedur volum
relationship daewoong
septemb enter daewoong agreement pursuant daewoong
agre manufactur suppli grant compani exclus
licens develop distribut market sell product cover territori daewoong also
grant non-exclus licens japan option subject
certain payment condit expand permit use product beyond aesthet indic
therapeut indic daewoong agreement requir make certain
minimum annual purchas upon commerci order maintain exclus licens
potenti minimum purchas oblig conting upon occurr futur event
includ receipt government approv futur market share variou jurisdict
connect entri daewoong agreement made up-front payment
daewoong million evolu agre make mileston payment upon certain
confidenti develop commerci mileston includ confidenti payment daewoong
upon fda ema approv daewoong agreement maximum
aggreg amount futur mileston payment could owe daewoong upon satisfact
mileston million daewoong agreement daewoong respons
cost relat manufactur includ cost relat oper upkeep
manufactur facil respons cost relat obtain regulatori
approv includ clinic expens commerci
term daewoong agreement purchas sell distribut
compet product cover territori japan sell product subject daewoong
agreement outsid cover territori japan initi term daewoong agreement
septemb later fifth anniversari approv relev government
author necessari market sell product ii septemb automat
renew addit three-year term meet certain perform requir either parti
may termin daewoong agreement written notic upon continu uncur default
parti daewoong agreement termin without notic upon bankruptci
presid ceo
dr simhambhatla join strathspey crown prior senior vice presid
presid abbott medic optic amo oper respons
global cataract lasik over-the-counter corneal busi prior amo dr simhambhatla led abbott
ibi bioscienc busi focus rapid broad detect pathogen respons
infect critic ill patient join abbott acquisit guidant vascular
busi vice presid gener manag drug elut stent
respons develop market lead xienc stent held varieti role
increas respons product develop new ventur intern commerci
oper vascular busi prior guidant dr simhambhatla start career
aerospac optoelectron industri raychem corpor menlo park dr simhambhatla
hold bachelor degre chemic engin anna univers india master
doctor degre polym engin univers akron
dr marmo found inc novemb within one year negoti suppli
distribut agreement daewoong pharmaceut botulinum toxin prior found
dr marmo held posit senior vice presid global research develop
allergan medic role charg direct staff peopl
area research develop clinic regulatori qualiti previous dr marmo vice
presid research develop coopervis ocular scienc year dr marmo
receiv bachelor degre union colleg doctor chemistri univers
dr avelar join januari began busi career buy side sell side
financi analyst cover med-tech sector spent year
angiotech pharmaceut inc initi vice-president investor relat chief medic
offic charg regulatori clinic oper clinic develop medic affair medic
write statist safeti qualiti experi cover devic pharmaceut drug-devic
combin biolog prior dr avelar act chief medic offic
allergan medic year tenur charg clinic develop clinic
oper safeti medic write statist regulatori dr avelar receiv medic degre
univers toronto went train accredit sport medicin
canadian academi sport medicin along privat practic vancouv
year consult number canadian nation team team physician
vancouv canuck nhl franchis year
mr garcia year experi overse aspect financi oper includ
experi financi report account practic cash manag account receiv
account payabl process background capit market transact includ ipo
merger acquisit financi due dilig prior join januari mr
garcia manag director advisori practic beacon provid sec
capit market consult servic mr garcia start career public account
pricewaterhous cooper pwc facilit audit engag special complex
revenu recognit equiti transact merger acquisit ipo left pwc
assur manag middl market audit practic mr garcia graduat bachelor
art degre concordia univers
arriv price target
use blend dcf multipl ev/ebitda analysi get price target
dcf analysi arriv share price use wacc exit
multipl forward ebit higher peer trade averag
forward ev/ebit assign higher ev/ebit multipl think
product durabl life cycl tradit specialti pharma product
cash pay aspect aesthet busi expos reimburs risk also
develop stage compani approv sale growth like
meaning higher peer
multipl ev/ebitda analysi arriv share price appli
forward ev/ebitda multipl evoluss ebitda estim subtract
debt ev add back cash arriv equiti valu divid equiti
valu share count get price per share discount back arriv
price per share forward ev/ebitda multipl appli ebitda higher
averag ev/ebitda multipl peer trade averag forward
assumpt except per share rate taxes- depreci less capit chang work free free termin dilut share cantor fitzgerald research compani reportsyear end decemb march
ev/ebitda multipl assign higher ev/ebitda multipl compani key
pipelin drug potenti gener greater long term valu peer due durabl
lack reimburs risk associ also develop stage
compani product approv sale growth like meaning higher
use follow compani peer ow akao
 follow william tanner arlz cemp derm ow edg
eglt ow fomx ow ipxl ow ow follow
follow william tanner vrx ow xene ow
would also note compar favor market cap similar publicli trade
compani sector averag market cap
exhibit overview similar publicli trade compani
evolusmarket cap similar publicli trade factset compani present websit compani identifi develop commerci novel drug address unmet need dermatolog also pursu develop topic agent treatment prevent number medic cosmet sk wart phase phase phase develop therapeut solut medic dermatolog treat skin condit hyperhidrosi psoriasi phase develop proprietari minocyclin foam treatment acn impetigo skin condit phase phase redefin standard care dermatolog develop commerci innov therapi use nitric oxid platform phase phase stage compani engag develop manufactur commerci novel botulinum toxin product multipl aesthet therapeut applic glabellar line phase cervicaldystonia phase plantar fasciiti phase overview similar publicli trade compani march
bull bear base case analysi
also use blend dcf multipl ev/ebitda analysi arriv bull
bear case scenario base analysi estim likelihood stock worth
next month
exhibit bull bear base case scenario analysi
assign higher probabl bull case scenario versu bear case scenario given
confid strength market opportun
evolussourc cantor fitzgerald research compani caselaunch launch product scenario caselaunch late earli launch product scenario caselaunch launch expand product offer scenario march
develop stage compani risk similar compani stage
develop specif compani would note three key potenti risk see
rate price target
market domin larger establish player
allergan botox merz xeomin ipsen/galderma dysport larger sale forc
market budget said dysport xeomin differ botox
caus problem launch
medytox lawsuit creat noise/uncertainti
medytox file lawsuit daewoong alphaeon well citizen petit
fda seek delay approv daewoong file motion dismiss stay forum
non convenien claim place complaint file superior court
state california proper place trial claim complaint
among reason underli fact gave rise complaint occur south korea
daewoong motion dismiss grant superior court state california octob
result action file superior court state california stay
pend resolut proceed south korea
issu fda novemb
fda conduct cgmp pre-approv inspect daewoong manufactur facil
south korea relat evoluss bla novemb novemb
end inspect fda issu fda ten inspect observ
daewoong daewoong time respond fda plan implement correct action
relat observ await respons fda daewoong inform
believ respons satisfi requir fda
signific action necessari
exhibit incom statement analysi
million compound-annual-growth-rate year end decemb revenu oper share chang yoytot cantor fitzgerald research compani nol approxim off-set tax initi year base tax return basi exhibit margin analysi
revenu cantor fitzgerald research compani report exhibit quarterli sale analysi
million year end decemb chang othernmnmnmnmnmnmnmnmnmnmnmnmnmnmnmtot cantor fitzgerald research compani report exhibit annual sale analysi
cantor fitzgerald research compani reportsyear end decemb exhibit analysi
million year end decemb flow provid oper activ net depreci net chang work net cash provid oper flow invest activitiespurchas pp e- net proce sale assets- acquisit net cash acquired- other- net cash use invest activities- flow financ activ repay issuanc long term proce issuanc stock- other- net cash use provid financ net decreas increas cash equivalents- equival begin year- equival end year- sourc cantor fitzgerald research compani report exhibit balanc sheet analysi
million year end decemb equivalents- account receiv less allow doubt accounts- inventories- current total current plant properti equipment- identifi assets- total total liabil sharehold equityaccount payabl accru total current long term debt total sharehold total stockhold non-controlling interest- total liabil stockhold sourc cantor fitzgerald research compani report march
medic aesthet compani focus provid physician patient expand choic medic aesthet
treatment procedur evolu primari market self-pay healthcar lead product candid inject formul
